321,405 Shares in OrthoPediatrics Corp. (NASDAQ:KIDS) Bought by Point72 Asset Management L.P.

Point72 Asset Management L.P. acquired a new position in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 321,405 shares of the company's stock, valued at approximately $7,450,000. Point72 Asset Management L.P. owned 1.33% of OrthoPediatrics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Invesco Ltd. raised its holdings in shares of OrthoPediatrics by 3.0% during the fourth quarter. Invesco Ltd. now owns 16,363 shares of the company's stock worth $379,000 after acquiring an additional 469 shares during the period. Northern Trust Corp raised its holdings in shares of OrthoPediatrics by 0.3% during the fourth quarter. Northern Trust Corp now owns 193,798 shares of the company's stock worth $4,492,000 after acquiring an additional 644 shares during the period. Rhumbline Advisers grew its position in OrthoPediatrics by 4.1% in the fourth quarter. Rhumbline Advisers now owns 26,411 shares of the company's stock valued at $612,000 after purchasing an additional 1,042 shares in the last quarter. R Squared Ltd bought a new position in OrthoPediatrics in the fourth quarter valued at $48,000. Finally, Bank of New York Mellon Corp grew its position in OrthoPediatrics by 3.8% in the fourth quarter. Bank of New York Mellon Corp now owns 57,710 shares of the company's stock valued at $1,338,000 after purchasing an additional 2,099 shares in the last quarter. 69.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other OrthoPediatrics news, General Counsel Daniel J. Gerritzen sold 5,310 shares of OrthoPediatrics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $132,006.60. Following the completion of the sale, the general counsel now owns 110,767 shares in the company, valued at $2,753,667.62. The trade was a 4.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David R. Bailey sold 6,620 shares of OrthoPediatrics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $164,573.20. Following the completion of the sale, the chief executive officer now owns 319,155 shares of the company's stock, valued at $7,934,193.30. This trade represents a 2.03% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,732 shares of company stock valued at $589,978. Company insiders own 32.70% of the company's stock.

OrthoPediatrics Stock Performance

Shares of KIDS opened at $22.95 on Tuesday. The company has a market cap of $557.39 million, a PE ratio of -18.66 and a beta of 1.09. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. The firm has a 50-day moving average of $22.80 and a 200-day moving average of $23.92. OrthoPediatrics Corp. has a one year low of $20.25 and a one year high of $35.99.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.13). The company had revenue of $52.41 million for the quarter, compared to the consensus estimate of $51.68 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. As a group, equities analysts forecast that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $42.00 target price on shares of OrthoPediatrics in a research report on Thursday, May 8th. Stifel Nicolaus decreased their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, March 5th. Truist Financial decreased their target price on shares of OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Piper Sandler decreased their target price on shares of OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Finally, Lake Street Capital began coverage on shares of OrthoPediatrics in a research report on Monday, April 7th. They issued a "buy" rating and a $37.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.83.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.